England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin
Red, a Huntsworth agency, also counted Sanofi as a new client.
Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
The company said growth in its immunology portfolio offset declining Olysio sales.
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.
The drugmaker recently launched a DTC campaign for diabetes drug Trulicity, which generated $73.7 million in sales in the third quarter.
The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.
The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.
Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.
First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.
The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.
Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.
Sales of the new cancer drug topped expectations since its February launch.
First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Established products fueled at 12% jump in first-quarter sales.
The holding company said pharma and health made up 11% of revenues during the first three months of the year.
The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.
The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.
Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.
CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.
Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.
The company raised guidance for the end of the year and said Ranbaxy's being bounced from the Nexium competition probably means it has esomeprazole market to itself through 2014.
Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.
GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.
Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.
- Which drugmakers have the healthiest presence on social media?
- Five things for pharma marketers to know: Monday, September 26, 2016
- Uber partners with startup to take patients to the doctor
- Five things for pharma marketers to know: Tuesday, September 27, 2016
- Five things for pharma marketers to know: Wednesday, September 28, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Drugmakers set their sights on the next potential blockbuster disease: NASH
- Five things for pharma marketers to know: Thursday, September 29, 2016
- BBDO picks up Neulasta; FCB gains Galderma and Sandoz work in the U.S.
- How to get more women in the C-suite, according to IPG, Unilever, and AOL
- Why Any Merger is the Last Resort of Lousy Marketers